Upstream Bio (UPB) Stock: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$2.74
-0.25 (-8.36%)
▼
5d:
-0.72%
30d:
-47.0%
90d:
-57.19%
HOLD
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $2.74, which is considered oversold relative to its 30-day fair value range of $3.55 to $5.52.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is currently testing key support at $2.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: UPB scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.14 (+1036.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is currently testing key support at $2.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: UPB scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.14 (+1036.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.55 -
$5.52
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 1036.6% below Wall St target ($31.14)
- CAUTION: Bottoming setup, but lagging the sector by 35% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$3.55 -
$5.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.70
Resistance Level
$4.72
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.98
Wall Street Target
$31.14
(+1036.6%)
Revenue Growth (YoY)
-17.5%
Share & Embed Analysis
Last updated: October 23, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
